Servier and MiNA Therapeutics sign €220m deal

Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialisation of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics can receive up to €220m including an upfront payment, an exclusivity fee on selected neurological targets and milestone payments as well as royalties.

saRNAs activate gene expression thus unlocking potential for the treatment of neurodegenerative diseases with limited treatment options, particularly in the neurology and immuno-inflammation area. The collaboration is an extension to MiNA Therapeutics’ R&D activities that has been so far focussed on liver cancer.